{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:20:50Z","timestamp":1789993250401,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T00:00:00Z","timestamp":1507161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1038\/hr.2017.83","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T06:01:02Z","timestamp":1507183262000},"page":"8-17","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Role of bardoxolone methyl, a nuclear factor erythroid 2-related factor 2 activator, in aldosterone- and salt-induced renal injury"],"prefix":"10.1038","volume":"41","author":[{"given":"Mikako","family":"Hisamichi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Kamijo-Ikemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Sugaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiko","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Shibagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,5]]},"reference":[{"key":"BFhr201783_CR1","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1161\/HYPERTENSIONAHA.109.149062","volume":"55","author":"T Fujita","year":"2010","unstructured":"Fujita T . Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome. Hypertension 2010; 55: 813\u2013818.","journal-title":"Hypertension"},{"key":"BFhr201783_CR2","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","volume":"63","author":"ER Blasi","year":"2003","unstructured":"Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG . Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63: 1791\u20131800.","journal-title":"Kidney Int"},{"key":"BFhr201783_CR3","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1681\/ASN.2011070734","volume":"23","author":"W Kawarazaki","year":"2012","unstructured":"Kawarazaki W, Nagase M, Yoshida S, Takeuchi M, Ishizawa K, Ayuzawa N, Ueda K, Fujita T . Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation. J Am Soc Nephrol 2012; 23: 997\u20131007.","journal-title":"J Am Soc Nephrol"},{"key":"BFhr201783_CR4","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1161\/01.HYP.0000222003.28517.99","volume":"47","author":"M Nagase","year":"2006","unstructured":"Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T . Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006; 47: 1084\u20131093.","journal-title":"Hypertension"},{"key":"BFhr201783_CR5","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","volume":"2","author":"K Ando","year":"2014","unstructured":"Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T . Group ES: Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2014; 2: 944\u2013953.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"BFhr201783_CR6","doi-asserted-by":"publisher","first-page":"542","DOI":"10.2215\/CJN.04750908","volume":"4","author":"SD Navaneethan","year":"2009","unstructured":"Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF . Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4: 542\u2013551.","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFhr201783_CR7","doi-asserted-by":"publisher","first-page":"F833","DOI":"10.1152\/ajprenal.00557.2010","volume":"301","author":"J Irita","year":"2011","unstructured":"Irita J, Okura T, Jotoku M, Nagao T, Enomoto D, Kurata M, Desilva VR, Miyoshi K, Matsui Y, Uede T, Denhardt DT, Rittiling SR, Higaki J . Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney. Am J Physiol Renal Physiol 2011; 301: F833\u2013F844.","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFhr201783_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/nrneph.2012.282","volume":"9","author":"M Nagase","year":"2013","unstructured":"Nagase M, Fujita T . Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat Rev Nephrol 2013; 9: 86\u201398.","journal-title":"Nat Rev Nephrol"},{"key":"BFhr201783_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1254\/jphs.08R02CR","volume":"108","author":"H Kiyomoto","year":"2008","unstructured":"Kiyomoto H, Rafiq K, Mostofa M, Nishiyama A . Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury. J Pharm Sci 2008; 108: 399\u2013405.","journal-title":"J Pharm Sci"},{"key":"BFhr201783_CR10","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1161\/01.HYP.0000118519.66430.22","volume":"43","author":"A Nishiyama","year":"2004","unstructured":"Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, Kondo S, Kiyomoto H, Shokoji T, Kimura S, Kohno M, Abe Y . Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone\/salt-induced hypertensive rats. Hypertension 2004; 43: 841\u2013848.","journal-title":"Hypertension"},{"key":"BFhr201783_CR11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","volume":"49","author":"S Shibata","year":"2007","unstructured":"Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T . Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007; 49: 355\u2013364.","journal-title":"Hypertension"},{"key":"BFhr201783_CR12","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1681\/ASN.2005121375","volume":"17","author":"GP Sun","year":"2006","unstructured":"Sun GP, Kohno M, Guo P, Nagai Y, Miyata K, Fan YY, Kimura S, Kiyomoto H, Ohmori K, Li DT, Abe Y, Nishiyama A . Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol 2006; 17: 2193\u20132201.","journal-title":"J Am Soc Nephrol"},{"key":"BFhr201783_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/path.4049","volume":"228","author":"M Prunotto","year":"2012","unstructured":"Prunotto M, Budd DC, Gabbiani G, Meier M, Formentini I, Hartmann G, Pomposiello S, Moll S . Epithelial-mesenchymal crosstalk alteration in kidney fibrosis. J Pathol 2012; 228: 131\u2013147.","journal-title":"J Pathol"},{"key":"BFhr201783_CR14","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJM199811123392007","volume":"339","author":"G Remuzzi","year":"1998","unstructured":"Remuzzi G, Bertani T . Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448\u20131456.","journal-title":"N Engl J Med"},{"key":"BFhr201783_CR15","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1194\/jlr.M900177-JLR200","volume":"50","author":"J Yan","year":"2009","unstructured":"Yan J, Gong Y, She YM, Wang G, Roberts MS, Burczynski FJ . Molecular mechanism of recombinant liver fatty acid binding protein's antioxidant activity. J Lipid Res 2009; 50: 2445\u20132454.","journal-title":"J Lipid Res"},{"key":"BFhr201783_CR16","doi-asserted-by":"crossref","first-page":"18345","DOI":"10.1016\/S0021-9258(17)46851-7","volume":"268","author":"TC Simon","year":"1993","unstructured":"Simon TC, Roth KA, Gordon JI . Use of transgenic mice to map cis-acting elements in the liver fatty acid-binding protein gene (Fabpl) that regulate its cell lineage-specific, differentiation-dependent, and spatial patterns of expression in the gut epithelium and in the liver acinus. J Biol Chem 1993; 268: 18345\u201318358.","journal-title":"J Biol Chem"},{"key":"BFhr201783_CR17","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/S0002-9440(10)63384-6","volume":"165","author":"A Kamijo","year":"2004","unstructured":"Kamijo A, Sugaya T, Hikawa A, Okada M, Okumura F, Yamanouchi M, Honda A, Okabe M, Fujino T, Hirata Y, Omata M, Kaneko R, Fujii H, Fukamizu A, Kimura K . Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 2004; 165: 1243\u20131255.","journal-title":"Am J Pathol"},{"key":"BFhr201783_CR18","doi-asserted-by":"publisher","first-page":"F114","DOI":"10.1152\/ajprenal.00469.2014","volume":"308","author":"D Ichikawa","year":"2015","unstructured":"Ichikawa D, Kamijo-Ikemori A, Sugaya T, Shibagaki Y, Yasuda T, Hoshino S, Katayama K, Igarashi-Migitaka J, Hirata K, Kimura K . Human liver-type fatty acid-binding protein protects against tubulointerstitial injury in aldosterone-induced renal injury. Am J Physiol Renal Physiol 2015; 308: F114\u2013F121.","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFhr201783_CR19","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1096\/fj.04-2591hyp","volume":"19","author":"JM Lee","year":"2005","unstructured":"Lee JM, Li J, Johnson DA, Stein TD, Kraft AD, Calkins MJ, Jakel RJ, Johnson JA . Nrf2, a multi-organ protector? FASEB J 2005; 19: 1061\u20131066.","journal-title":"FASEB J"},{"key":"BFhr201783_CR20","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1365-2443.2008.01234.x","volume":"13","author":"K Yoh","year":"2008","unstructured":"Yoh K, Hirayama A, Ishizaki K, Yamada A, Takeuchi M, Yamagishi S, Morito N, Nakano T, Ojima M, Shimohata H, Itoh K, Takahashi S, Yamamoto M . Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells 2008; 13: 1159\u20131170.","journal-title":"Genes Cells"},{"key":"BFhr201783_CR21","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1046\/j.1523-1755.2001.00939.x","volume":"60","author":"K Yoh","year":"2001","unstructured":"Yoh K, Itoh K, Enomoto A, Hirayama A, Yamaguchi N, Kobayashi M, Morito N, Koyama A, Yamamoto M, Takahashi S . Nrf2-deficient female mice develop lupus-like autoimmune nephritis. Kidney Int 2001; 60: 1343\u20131353.","journal-title":"Kidney Int"},{"key":"BFhr201783_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.kint.2016.08.023","volume":"91","author":"M Nezu","year":"2017","unstructured":"Nezu M, Souma T, Yu L, Suzuki T, Saigusa D, Ito S, Suzuki N, Yamamoto M . Transcription factor Nrf2 hyperactivation in early-phase renal ischemia-reperfusion injury prevents tubular damage progression. Kidney Int 2017; 91: 387\u2013401.","journal-title":"Kidney Int"},{"key":"BFhr201783_CR23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1105351","volume":"365","author":"PE Pergola","year":"2011","unstructured":"Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Wittes J, Warnock DG, Investigators BS. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011; 365: 327\u2013336.","journal-title":"N Engl J Med"},{"key":"BFhr201783_CR24","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1161\/HYPERTENSIONAHA.115.06163","volume":"66","author":"RA Lopes","year":"2015","unstructured":"Lopes RA, Neves KB, Tostes RC, Montezano AC, Touyz RM . Downregulation of nuclear factor erythroid 2-related factor and associated antioxidant genes contributes to redox-sensitive vascular dysfunction in hypertension. Hypertension 2015; 66: 1240\u20131250.","journal-title":"Hypertension"},{"key":"BFhr201783_CR25","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1161\/HYPERTENSIONAHA.112.199828","volume":"60","author":"D Ichikawa","year":"2012","unstructured":"Ichikawa D, Kamijo-Ikemori A, Sugaya T, Yasuda T, Hoshino S, Igarashi-Migitaka J, Hirata K, Kimura K . Renal liver-type fatty acid binding protein attenuates angiotensin II-induced renal injury. Hypertension 2012; 60: 973\u2013980.","journal-title":"Hypertension"},{"key":"BFhr201783_CR26","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.ajpath.2010.12.002","volume":"178","author":"K Matsui","year":"2011","unstructured":"Matsui K, Kamijo-Ikemori A, Sugaya T, Yasuda T, Kimura K . Renal liver-type fatty acid binding protein (L-FABP) attenuates acute kidney injury in aristolochic acid nephrotoxicity. Am J Pathol 2011; 178: 1021\u20131032.","journal-title":"Am J Pathol"},{"key":"BFhr201783_CR27","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.2353\/ajpath.2009.080780","volume":"174","author":"T Yokoyama","year":"2009","unstructured":"Yokoyama T, Kamijo-Ikemori A, Sugaya T, Hoshino S, Yasuda T, Kimura K . Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage. Am J Pathol 2009; 174: 2096\u20132106.","journal-title":"Am J Pathol"},{"key":"BFhr201783_CR28","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/j.1349-7006.2012.02216.x","volume":"103","author":"D Inoue","year":"2012","unstructured":"Inoue D, Suzuki T, Mitsuishi Y, Miki Y, Suzuki S, Sugawara S, Watanabe M, Sakurada A, Endo C, Uruno A, Sasano H, Nakagawa T, Satoh K, Tanaka N, Kubo H, Motohashi H, Yamamoto M . Accumulation of p62\/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Sci 2012; 103: 760\u2013766.","journal-title":"Cancer Sci"},{"key":"BFhr201783_CR29","doi-asserted-by":"publisher","first-page":"F655","DOI":"10.1152\/ajprenal.00460.2013","volume":"306","author":"D Ichikawa","year":"2014","unstructured":"Ichikawa D, Kamijo-Ikemori A, Sugaya T, Shibagaki Y, Yasuda T, Katayama K, Hoshino S, Igarashi-Migitaka J, Hirata K, Kimura K . Renoprotective effect of renal liver-type fatty acid binding protein and angiotensin II type 1a receptor loss in renal injury caused by RAS activation. Am J Physiol Renal Physiol 2014; 306: F655\u2013F663.","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFhr201783_CR30","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1681\/ASN.2011080822","volume":"23","author":"V Lopez-Parra","year":"2012","unstructured":"Lopez-Parra V, Mallavia B, Lopez-Franco O, Ortiz-Munoz G, Oguiza A, Recio C, Blanco J, Nimmerjahn F, Egido J, Gomez-Guerrero C . Fcgamma receptor deficiency attenuates diabetic nephropathy. J Am Soc Nephrol 2012; 23: 1518\u20131527.","journal-title":"J Am Soc Nephrol"},{"key":"BFhr201783_CR31","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1021\/np100826q","volume":"74","author":"MB Sporn","year":"2011","unstructured":"Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM, Gribble GW . New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J Nat Prod 2011; 74: 537\u2013545.","journal-title":"J Nat Prod"},{"key":"BFhr201783_CR32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/1535-7163.MCT-06-0516","volume":"6","author":"MS Yates","year":"2007","unstructured":"Yates MS, Tauchi M, Katsuoka F, Flanders KC, Liby KT, Honda T, Gribble GW, Johnson DA, Johnson JA, Burton NC, Guilarte TR, Yamamoto M, Sporn MB, Kensler TW . Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther 2007; 6: 154\u2013162.","journal-title":"Mol Cancer Ther"},{"key":"BFhr201783_CR33","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/ki.2012.393","volume":"83","author":"Y Ding","year":"2013","unstructured":"Ding Y, Stidham RD, Bumeister R, Trevino I, Winters A, Sprouse M, Ding M, Ferguson DA, Meyer CJ, Wigley WC, Ma R . The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells. Kidney Int 2013; 83: 845\u2013854.","journal-title":"Kidney Int"},{"key":"BFhr201783_CR34","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/ajh.2011.200","volume":"25","author":"GV Senanayake","year":"2012","unstructured":"Senanayake GV, Banigesh A, Wu L, Lee P, Juurlink BH . The dietary phase 2 protein inducer sulforaphane can normalize the kidney epigenome and improve blood pressure in hypertensive rats. Amournal J Hypertens 2012; 25: 229\u2013235.","journal-title":"Amournal J Hypertens"},{"key":"BFhr201783_CR35","doi-asserted-by":"publisher","first-page":"7094","DOI":"10.1073\/pnas.0402004101","volume":"101","author":"L Wu","year":"2004","unstructured":"Wu L, Noyan Ashraf MH, Facci M, Wang R, Paterson PG, Ferrie A, Juurlink BH . Dietary approach to attenuate oxidative stress, hypertension, and inflammation in the cardiovascular system. Proc Natl Acad Sci USA 2004; 101: 7094\u20137099.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFhr201783_CR36","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/hr.2015.13","volume":"38","author":"H Sawada","year":"2015","unstructured":"Sawada H, Naito Y, Oboshi M, Iwasaku T, Okuhara Y, Morisawa D, Eguchi A, Hirotani S, Masuyama T . Iron restriction inhibits renal injury in aldosterone\/salt-induced hypertensive mice. Hypertens Res 2015; 38: 317\u2013322.","journal-title":"Hypertens Res"},{"key":"BFhr201783_CR37","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1002\/eji.201041316","volume":"41","author":"S Freigang","year":"2011","unstructured":"Freigang S, Ampenberger F, Spohn G, Heer S, Shamshiev AT, Kisielow J, Hersberger M, Yamamoto M, Bachmann MF, Kopf M . Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur J Immunol 2011; 41: 2040\u20132051.","journal-title":"Eur J Immunol"},{"key":"BFhr201783_CR38","doi-asserted-by":"publisher","first-page":"17020","DOI":"10.1074\/jbc.M114.563114","volume":"289","author":"C Zhao","year":"2014","unstructured":"Zhao C, Gillette DD, Li X, Zhang Z, Wen H . Nuclear factor E2-related factor-2 (Nrf2) is required for NLRP3 and AIM2 inflammasome activation. J Biol Chem 2014; 289: 17020\u201317029.","journal-title":"J Biol Chem"},{"key":"BFhr201783_CR39","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","volume":"369","author":"D de Zeeuw","year":"2013","unstructured":"de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM Investigators BT. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013; 369: 2492\u20132503.","journal-title":"N Engl J Med"},{"key":"BFhr201783_CR40","doi-asserted-by":"publisher","first-page":"F808","DOI":"10.1152\/ajprenal.00376.2012","volume":"304","author":"C Zoja","year":"2013","unstructured":"Zoja C, Corna D, Nava V, Locatelli M, Abbate M, Gaspari F, Carrara F, Sangalli F, Remuzzi G, Benigni A . Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. Am J Physiol Renal Physiol 2013; 304: F808\u2013F819.","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFhr201783_CR41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.lab.2003.08.001","volume":"143","author":"A Kamijo","year":"2004","unstructured":"Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Hikawa A, Hirano N, Hirata Y, Goto A, Omata M . Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 2004; 143: 23\u201330.","journal-title":"J Lab Clin Med"},{"key":"BFhr201783_CR42","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1681\/ASN.2012050457","volume":"23","author":"SA Reisman","year":"2012","unstructured":"Reisman SA, Chertow GM, Hebbar S, Vaziri ND, Ward KW, Meyer CJ . Bardoxolone methyl decreases megalin and activates nrf2 in the kidney. J Am Soc Nephrol 2012; 23: 1663\u20131673.","journal-title":"J Am Soc Nephrol"},{"key":"BFhr201783_CR43","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1001\/archinte.168.8.832","volume":"168","author":"LJ Appel","year":"2008","unstructured":"Appel LJ, Wright JT Jr., Greene T, Kusek JW, Lewis JB, Wang X, Lipkowitz MS, Norris KC, Bakris GL, Rahman M, Contreras G, Rostand SG, Kopple JD, Gabbai FB, Schulman GI, Gassman JJ, Charleston J, Agodoa LY African American Study of Kidney D Hypertension Collaborative Research G. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med 2008; 168: 832\u2013839.","journal-title":"Arch Intern Med"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/hr201783.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr201783","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/hr.2017.83","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/hr201783.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T14:24:22Z","timestamp":1719498262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr201783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,5]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["BFhr201783"],"URL":"https:\/\/doi.org\/10.1038\/hr.2017.83","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,5]]},"assertion":[{"value":"30 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TS is the director and senior scientist of CMIC HOLDINGS Co., Ltd., the company that produced the kits for L-FABP analysis. All other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}